SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer.

ABSTRACT:

Background

Currently, no biomarkers of response to mitomycin C have been identified in non-muscle-invasive bladder cancer patients. Predictive biomarkers could improve the treatment outcome and eliminate adverse events from unnecessary treatment.

Objective

To identify and validate predictive biomarkers of chemoresection with mitomycin C.

Design setting and participants

The intervention group of a randomised controlled trial was identified for analyses. The study was conducted between January 2018 and June 2019 in two major urological departments in Denmark. Patients had a history of Ta low-grade/high-grade disease and were included upon recurrence. The intervention group (58 patients) received chemoresection with mitomycin C. Tumour and reference germline DNA from pri

SUBMITTER: Lindgren MS 

PROVIDER: S-EPMC8655384 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature